Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., . . . Tortora, G. (2015). Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One.
Chicago Style CitationCarbognin, Luisa, et al. "Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A According to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers." PLoS One 2015.
MLA CitationCarbognin, Luisa, et al. "Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A According to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers." PLoS One 2015.